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Introduction
HIV-1 protease (PR) cleaves Gag and Gag-Pol polyproteins during virus maturation. Gag
mutations involving cleavage sites, in particular p7/p1, p1/p6, have been associated with
drug resistance or recovery of replicative capacity (RC) both in the absence[1] and presence
[2-4] of PR drug resistance associated mutations. Polymorphisms at these positions as well
as the p24/p2 and p2/p7 cleavage site have also been documented in drug naïve patients [3,
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5]. Furthermore, we and others have identified areas of the Gag protein from PI-treated
patients that are associated with both drug resistance and recovery of RC (outside cleavage
site regions) [6-8]. Polymorphisms throughout gag may therefore be relevant to response to
PIs in naïve patients. Despite this body of data, phenotypic testing of clinical samples is still
focused primarily on the protease gene. Phenotypic resistance test vectors have generally
incorporated patient derived Protease and the 5′ end of gag (including p7/p1 and p1/p6
cleavage sites) into a gag containing vector, typically derived from an HIV-1 subtype B
molecular clone. There exists therefore the possibility of misclassifying drug susceptibility
based on such an approach.
Non-B subtypes of HIV-1 account for the vast majority of infections worldwide. As the
WHO public health rollout of HAART progresses substantial numbers of patients will
require second line therapy with ritonavir-boosted protease inhibitors (PI). Since little in
vitro work has been undertaken on the basis of PI susceptibility in full length non B viruses
we focused on PI drug susceptibility in wild type subtype A and C laboratory and clinical
strains, not previously exposed to antiretrovirals, as these different subtypes provide a wide
genetic diversity within protease and gag. We sought to explore the role of full-length gag as
well as protease in determining PI susceptibility in such wild type viruses.
Materials and Methods
Construction of resistance test vectors
A replication defective, envelope deleted subtype B clone p8.91NSX, expressing gag-pol, tat
and rev was used as previously described [6]. This vector was further modified by silencing
an existing EcoRI site at the end of integrase and creating a new EcoRI site just after the end
of protease using site directed mutagenesis to allow cloning of gag-protease sequences. The
two vectors had indistinguishable replication capacities and drug susceptibility profiles (data
not shown). We obtained the following molecular clones from the NIH AIDS Research and
Reference Reagent program: (subtype) p97ZA012.1 (C)[9], p8CN006.29 (C)[9], pMJ4 (C)
[10], p94CY017.41 (A)[11]. Additionally the gag-protease region was amplified from two
treatment naïve patients, identified by phylogenetic analysis as having subtype A virus
during routine genotypic testing at first HIV diagnosis. RNA was extracted from plasma
virus (QIA amp® viral RNA extraction kit, Qiagen,) and reverse transcribed using Moloney-
MLV-RT and random priming (Promega). Gag-pol coding sequence was amplified from
cDNA by nested PCR using outer primers 5′gagout (GTG TGG AAA ATC TCT AGC AG)
and RTrev1 (CTG GRA TAA CYT CTG CTT) and an inner primer set as described[6].
Both PCR steps were carried out using Expand® High Fidelity PCR kit (Boehringer
Manheim). The subtype A gag-protease sequences were cloned into the vector backbone,
and representative clones (12.2 and 32G) chosen that had the same pol sequence as
determined from plasma virus population sequencing. We utilized the naturally occurring
ApaI restriction site towards the end of gag to generate chimeras between the test samples
and the subtype B reference virus as used by commercial phenotypic systems.
Generation of virus stocks and drug susceptibility testing
293T cells were cotransfected with a gag-pol expression vector containing cloned gag-
protease sequences, and plasmids encoding VSV-G envelope and luciferase reporter genes,
with PI drug susceptibility testing carried out as previously described [6]. Results, derived
from at least two independent experiments (each in duplicate) were analyzed and IC50
determined using Graph Pad Prism 5 (GraphPad Software, Inc. La Jolla, CA, USA).
Susceptibility testing for RT inhibitors differed in that supernatant containing resistance test
vectors was harvested 48 hours post transfection, and used to infect fresh target 293T cells
in the presence of serial dilutions of RT inhibitors in a 96 well plate format. Replicative
GUPTA et al. Page 2









capacity (RC) of these viruses was assessed by comparing the luciferase activity of
recombinant virus to that of the wild type subtype B control virus in the absence of drug.
Equal amounts of input plasmid DNA were used and we have previously shown that %
infectivity correlates well with infectivity/ ng p24 in this system[6]. The drugs used in this
study (ATV, DRV, LPV, SQV, AZT and NVP) were obtained from the AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID, NIH.
Multiple sequence alignment
was carried out using the program Muscle (www.drive5.com/muscle/) with manual
alignment in Se-Al (tree.bio.ed.ac.uk).
Results
Discrepancy between gag-protease and protease alone vectors in PI susceptibility
We tested a panel of six viruses against the following PIs: Atazanavir (ATV), Darunavir
(DRV), Lopinavir (LPV) and Saquinavir (SQV). Fold changes relative to subtype B are
shown in Table 1. For full-length gag-pro constructs we observed a range of PI
susceptibilities, with 5 out of 6 showing reduced susceptibility for at least one drug (using a
generous biological cut-off of FC>2, which is greater than the assay variability as
determined by the standard deviations of repeated IC50 values for the reference virus).
Overall, there was a 5-fold reduction in susceptibility to at least one drug in half the samples
tested, with the greatest reductions seen for lopinavir, with more variable changes in
susceptibility for atazanavir and saquinavir.
Importantly however, when specific proteases from these viruses were tested in the context
of the subtype B gag (table 1), as in most commercially available phenotypic drug resistance
assays, a reversal of this reduction in susceptibility was generally observed. This use of the
protease alone vector resulted in overestimating the LPV susceptibility of CY017 by nearly
25 times, of ZA012 by nearly 9 times and for 32G by a factor of 7, compared to the gag-
protease vector (table 1).
Gag alone confers reduced PI susceptibility
In order to determine if the determinants of reduced susceptibility in some of the viruses
were located in gag, we examined the profile of our panel of gag sequences fused not with
their cognate protease, but with the reference subtype B protease (Fig 1A) and compared
these to the full-length cognate gag-protease samples with regard to LPV susceptibility
(Table 1). We confirmed that gag alone determined reduced susceptibility to PI. Notably,
ZA012 gag with B protease showed 14-fold reduced susceptibility as compared to subtype B
gag-pro. This experiment also demonstrates that the cognate protease restores susceptibility
to PI and in the extreme case of MJ4, can completely reverse a partially resistant phenotype
to a hyper-susceptible one, in relation to subtype B.
There was variation in replicative capacity between constructs (Figure 1B). Interestingly the
cognate gag-protease combination had a lower RC than gag with a subtype B protease in
both ZA012 and 32G. There was no direct correlation between PI susceptibility and RC; for
example there was an 8.9 fold difference in LPV FC for gag-protease versus protease alone
in ZA012, but no difference in RC (Figure 1B, compare white and grey bars). As a control
for any potential impact of replication capacity on drug susceptibility, we performed
phenotypic susceptibility testing for the panel of viral constructs against the RT inhibitors
zidovudine (Figure 1C) and nevirapine (data not shown). For both drugs, the fold changes
relative to the subtype B reference were less than 1.5 fold across all constructs tested. We
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also confirmed that use of cognate gag-pro or cognate gag-pro-RT did not affect PI
susceptibility results (Figure 1D).
Finally, we analysed gag and protease sequences from the seven viruses tested (Figures S1
and S2). Comparison of gag cleavage sites (in boxes) shows that most are highly conserved,
with the exception of p7/p2 (Figure S1, orange box). Protease sequence analysis showed no
major resistance mutations and typical non-B polymorphisms in subtypes A and C, some of
which are classified as minor resistance mutations (Figure S2).
Conclusions
Overall these data demonstrate that virus specific protease confers variable susceptibility to
PI, and more importantly suggest that consideration of protease alone may overestimate PI
susceptibility in viruses not previously exposed to this class of drugs. This could lead to
misclassification of susceptibility for some isolates, and potentially also limits assessment of
the genotype-phenotype relationships in drug experienced patients.
Given the expanding body of evidence showing that gag mutations are known to contribute
to PI resistance in treated patients, and in light of our data we recommend that full gag
sequences should be included in recombinant virus assays to determine PI susceptibility in
clinical isolates. We would also encourage a rapid expansion of full-length gag sequencing
in patients failing PI-based therapy, to populate the relevant relational databases increasingly
used to assess the clinical impact of HIV drug resistance. Gag genotypic determination to
guide patient care can be then be evaluated once specific Gag determinants of PI
susceptibility have been identified.
Lower clinical cut-offs of 5.2 and 10 fold have been proposed for ATV and LPV response
respectively [12, 13]. Although fold changes in our system may not be directly comparable,
we were concerned to observe that some viruses approached and even exceeded these
values. In the ACTG 5142 study 23% of patients starting boosted lopinavir had a viral load
>50 copies/ml after 2 years, as compared to 11% for NNRTI based regimens (p=0.003)[14].
Patients with viral failure after boosted PI (bPI) in this and other studies infrequently have
major protease resistance mutations[15, 16], although there is a lack of data on evolution of
Gag mutations. A better understanding of determinants in Gag reducing susceptibility to PI
might explain these observations.
Finally, our findings may have important implications for the public health approach to
ART. Increasing numbers of patients are moving to PI-based second line therapy following
the rollout of HARRT, and combined LPV/ritonavir is the most widely available PI in
resource poor settings. Some of the subtype A and C constructs studied demonstrated
particularly high FCs for this agent, and as resistance testing is not routinely performed in
these patients, further research is clearly warranted.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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(A) Schematic diagram of chimeras used Key: X (test sequence), B (reference subtype B
sequence), MA (matrix, or p17), CA (capsid, or p24), p2 (spacer peptide 1), p7
(nucleocapsid), p1 (spacer peptide 2), p6, pro (protease), RT (reverse transcriptase). (B)
Mean replicative capacity of study viruses expressed as % of wild type subtype B reference
(log10) (C) Mean fold change in IC50 for the panel of viruses against AZT. (D) Comparison
of mean fold change in LPV and DRV IC50 using cognate gag-pro-RT versus gag-pro for
two viruses (12.2 and MJ4).
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